These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 8366297)
41. An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer. Cooper EH; Forbes MA; Hancock AK; Price JJ; Parker D Br J Cancer; 1989 May; 59(5):797-800. PubMed ID: 2736216 [TBL] [Abstract][Full Text] [Related]
42. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen. Kopczyński Z; Thielemann A Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926 [TBL] [Abstract][Full Text] [Related]
43. Tumour-associated antigens in maternal and fetal blood. Hohlfeld P; Dang TT; Nahoul K; Daffos F; Forestier F Prenat Diagn; 1994 Oct; 14(10):907-12. PubMed ID: 7899266 [TBL] [Abstract][Full Text] [Related]
44. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
45. Clinical value of a mucin-like carcinoma-associated antigen (MCA) in patients with carcinomas of the kidney and the urinary collecting system. Miserez AR; Müller-Brand J; Rist M; Mäcke H Int J Biol Markers; 1991; 6(1):7-11. PubMed ID: 1856518 [TBL] [Abstract][Full Text] [Related]
46. Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer. Garcia MB; Blankenstein MA; van der Wall E; Nortier JW; Schornagel JH; Thijssen JH Breast Cancer Res Treat; 1990 Dec; 17(2):69-76. PubMed ID: 2096994 [TBL] [Abstract][Full Text] [Related]
47. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of the new Cobas Core IgE Total EIA in comparison to three commercial IgE immunoassays. de Weck AL; Schluchter M; Girardin P J Investig Allergol Clin Immunol; 1994; 4(1):5-11. PubMed ID: 8081542 [TBL] [Abstract][Full Text] [Related]
49. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma]. Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086 [TBL] [Abstract][Full Text] [Related]
50. Comparison Between a Manual Squamous Cell Carcinoma Antigen Assay and an Automated Assay in a Clinical Setting. Lee S; Kim J; Uh Y; Kim HS; Lee JH Lab Med; 2018 Jul; 49(3):254-258. PubMed ID: 29566170 [TBL] [Abstract][Full Text] [Related]
51. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362 [TBL] [Abstract][Full Text] [Related]
52. CA 549: the theorem of Bayes for obtaining cut-off values. Blasco R; Rodriguez Cortasa MJ; Barbero EM; Colmenarejo A; Munoz Calvo R Int J Biol Markers; 1992; 7(4):270. PubMed ID: 1491188 [No Abstract] [Full Text] [Related]
53. Cobas Core CA 19-9 II EIA: new CA 19-9 enzyme immunoassay with high correlation to radioimmunoassays. Birk B; Henne V; Hipp B; Meyer A Anticancer Res; 1997; 17(4B):2911-4. PubMed ID: 9329561 [TBL] [Abstract][Full Text] [Related]
54. MUC3 and MCA serum levels and steroid receptor content in breast cancer. Quaranta M; Coviello M; Daniele A; Abbate I; Durrant LG; Paradiso A; Schittulli F Int J Biol Markers; 2004; 19(2):109-14. PubMed ID: 15255542 [TBL] [Abstract][Full Text] [Related]
55. Validation of an automated enzyme immunoassay for Interleukin-6 for routine clinical use. Fraunberger P; Pfeiffer M; Cremer P; Holler E; Nagel D; Dehart I; Thein M; Walli AK; Seidel D Clin Chem Lab Med; 1998 Oct; 36(10):797-801. PubMed ID: 9853808 [TBL] [Abstract][Full Text] [Related]
56. MCA in patients with breast cancer: correlation with CEA and CA15-3. Molina R; Filella X; Mengual P; Prats M; Zanon G; Daniels M; Ballesta AM Int J Biol Markers; 1990; 5(1):14-21. PubMed ID: 2230347 [TBL] [Abstract][Full Text] [Related]
57. Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study. Stierer M; Rosen HR; Forster E; Moroz C Breast Cancer Res Treat; 1991 Nov; 19(3):283-8. PubMed ID: 1777647 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation). Berger A; Scherzed L; Stürmer M; Preiser W; Doerr HW; Rabenau HF J Clin Virol; 2002 Dec; 25 Suppl 3():S103-7. PubMed ID: 12467784 [TBL] [Abstract][Full Text] [Related]
59. Analytical and clinical evaluation of a procedure for measuring CA 15-3 in the IMx analyser. Ortega MD; Maestro ML; Encabo G; Varón C; Allende MT; Martinez I; Palacios G Tumour Biol; 1996; 17(2):110-6. PubMed ID: 8658013 [TBL] [Abstract][Full Text] [Related]
60. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]